We sought to determine whether a single dose of 177Lu-PSMA-617 (Lu) can induce an immunogenic priming effect improve outcomes men with mCRPC treated pembrolizumab (P). This was phase 1b trial patients (pts) progression (PD) on at least one prior androgen receptor (AR) signaling inhibitor (NCT03805594). Pts were required have ≥ 3 PSMA-avid lesions 68Ga-PSMA-11 PET. No genomic selection undertake...

The limitation of specific delivery of photosensitizers to tumor sites, represents a significant shortcoming of photodynamic therapy (PDT) application at present. Prostate-specific membrane antigen (PSMA), a validated biomarker for prostate cancer, has attracted considerable attention as a target for imaging and therapeutic applications for prostate cancer. The present study focuses on the inve...

Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer. PSMA is a unique cell surface marker, negatively regulated by androgen and extensively used for imaging of hormone refractory carcinomas and metastatic foci. PSMA is a carboxypeptidase with two important enzymatic functions, namely, folate hydrolase and NAALADase. PSMA also exhi...